SCHEMBL3598802

SCHEMBL3598802

CN1C(=O)COc2c(NC(=O)/C=C3\CC4(CCC4)Oc4cc(C(F)(F)F)ccc43)cccc21

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 12/20 0.37
RAF1 P04049 1/20 0.34
TRPM8 Q7Z2W7 3/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545481 0.94 RAF1 (0.40) TRPV1RAF1
SCHEMBL3595556 0.90 TRPV1 (0.36) TRPV1TRPM8TP53MAPT
SCHEMBL3599786 0.90 RAF1 (0.36) TRPV1RAF1TRPM8TP53MAPT
SCHEMBL3587921 0.89 TP53 (0.38) TRPV1RAF1TRPM8TP53MAPT
SCHEMBL3601865 0.88 TRPV1 (0.45) TRPV1TP53MAPT
SCHEMBL3588769 0.87 TRPV1 (0.35) TRPV1TRPM8MAPT
SCHEMBL3588770 0.87 TRPV1 (0.35) TRPV1TRPM8MAPT
SCHEMBL3601764 0.87 TRPV1 (0.42) TRPV1
SCHEMBL3594922 0.84 TRPV1 (0.41) TRPV1
SCHEMBL4446985 0.83 TRPV1 (0.56) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885RAF1 1753/4885TRPM8 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.